History of interstitial lung disease or pneumonitisXx_NEWLINE_xXTREATMENT: Patients with current or a history of interstitial lung disease, known severely impaired lung function (spirometry and carbon monoxide diffusing capability test (DLCO) 50% or less of normal and oxygen [O2] saturation 88% or less at rest on room air) or non-infectious pneumonitis will not be assigned treatment with everolimus or trametinib DMSO; symptoms should have resolved and course of antibiotics been completed for patients with a history of infectious pneumonitis to be eligibleXx_NEWLINE_xXHistory of interstitial lung disease or pneumonitisXx_NEWLINE_xXHistory of interstitial lung disease or pneumonitisXx_NEWLINE_xXHistory of interstitial lung disease or pneumonitisXx_NEWLINE_xXHistory of interstitial lung disease or pneumonitisXx_NEWLINE_xXHistory of interstitial lung disease or pneumonitisXx_NEWLINE_xXPatients with a history of interstitial lung disease or pneumonitisXx_NEWLINE_xXHistory of interstitial lung disease or pneumonitisXx_NEWLINE_xXPatients must not have a history of pneumonitis or interstitial lung diseaseXx_NEWLINE_xXNo known interstitial fibrosis or interstitial lung diseaseXx_NEWLINE_xXPatients must not have evidence of interstitial lung disease or pneumonitisXx_NEWLINE_xXInterstitial lung disease or pneumonitis not secondary to ECDXx_NEWLINE_xXPatients must not have any known clinically active interstitial lung diseaseXx_NEWLINE_xXPast history of any lung cancerXx_NEWLINE_xXPrevious history of lung cancerXx_NEWLINE_xXSubjects with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity; NOTE: subjects must have baseline oxygen/saturation level requirements as aboveXx_NEWLINE_xXPast medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis requiring steroid treatment, or any evidence of clinically active interstitial lung diseaseXx_NEWLINE_xXAny serious intercurrent or psychiatric illness that could, in the investigatorï¿½s opinion, potentially interfere with the completion of treatment according to this protocol including but not limited to: * Uncontrolled diabetes mellitus (fasting plasma glucose > 130 mg/dL or 7.2 mmol/L)* Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease* Active infections * Gastrointestinal disease limiting the ability to swallow oral medications or absorb oral medications including refractory nausea and vomiting, chronic gastrointestinal diseases, inflammatory bowel disease; malabsorption syndromes* Patients with enteric stomata or significant bowel resection* Prior history of corneal ulceration* Patients with any evidence of severe or uncontrolled systemic liver disease including those with known hepatitis B and hepatitis C (excluding treated hepatitis C that has been cured)* Active bleeding diathesesXx_NEWLINE_xXPast medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis requiring steroid treatment, or any evidence of clinically active interstitial lung diseaseXx_NEWLINE_xXClinically significant lung disease including known history or evidence of interstitial lung disease or chronic obstructive pulmonary disease (COPD) that requires oxygen therapyXx_NEWLINE_xXPatients must not have known interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicityXx_NEWLINE_xXPatients with known and confirmed diagnosis of interstitial lung disease (IDL)Xx_NEWLINE_xXCLINICAL/LABORATORY CRITERIA: Patient must not have prior history of interstitial lung disease or pneumonitisXx_NEWLINE_xXPatients must not have interstitial lung disease that is symptomatic or disease that may interfere with the detection or management of suspected drug-related pulmonary toxicityXx_NEWLINE_xXHistory or concurrent condition of interstitial lung disease of any severity and/or severely impaired lung function (as judged by the investigator)Xx_NEWLINE_xXPatients must not have symptomatic interstitial lung disease or pneumonitisXx_NEWLINE_xXSubjects with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicityXx_NEWLINE_xXPresence of cavitation of central pulmonary lesion, or radiographic evidence of pneumonitis or other extensive bilateral lung disease such as interstitial lung diseaseXx_NEWLINE_xXPatients with interstitial lung disease and/or pneumonitis are not eligibleXx_NEWLINE_xXPast medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung diseaseXx_NEWLINE_xXHistory of interstitial lung disease or pneumonitis requiring supplemental oxygen or treatment with oral or intravenously administered corticosteroidsXx_NEWLINE_xX